Roche Holding AG (ROG.VX)

ROG.VX on Virt-X Level 1

275.30CHF
2 Jun 2015
Change (% chg)

-- (--)
Prev Close
CHF275.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,668,122
52-wk High
CHF295.80
52-wk Low
CHF238.80

ROG.VX

Chart for ROG.VX

About

Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. It discovers, develops and provides diagnostic and therapeutic products and services from early detection and prevention of diseases to diagnosis, treatment and treatment monitoring. The Company has two divisions: Pharmaceuticals and Diagnostics. It... (more)

Overall

Beta: 0.92
Market Cap(Mil.): CHF240,666.80
Shares Outstanding(Mil.): 862.56
Dividend: 8.00
Yield (%): 2.86

Financials

  ROG.VX Industry Sector
P/E (TTM): 25.87 36.48 38.67
EPS (TTM): 10.81 -- --
ROI: 20.07 16.42 15.73
ROE: 48.00 17.24 16.79
Search Stocks

BRIEF-Roche says to collaborate with Amgen on cancer study

* Roche announces a collaboration with Amgen on a phase 1b study to evaluate the safety and efficacy of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with Roche's investigational anti-PDL1 therapy atezolizumab, in patients with triple-negative breast cancer and colorectal cancer with liver metastases

1:10am EDT

European shares end steady as oil stocks offset real estate rally

LONDON, June 1 - European equities steadied at the close on Monday, with stronger real estate and healthcare offsetting weaker energy stocks, which tracked a sharp drop in crude oil prices.

01 Jun 2015

Pharma and real estate firms help European shares to edge higher

LONDON, June 1 - European equities rose in late trading on Monday, with Roche leading drug stocks higher following an encouraging company update and real estate shares getting some support from a positive sector note from JP Morgan.

01 Jun 2015

BRIEF-Roche says Avastin improves survival in thoracic cancer patients

* Roche says phase III study shows Avastin drug improves survival in patients with mesothelioma, a type of thoracic cancer

30 May 2015

BRIEF-Roche U.S. FDA grants waiver for cobas Strep A test

* Roche says the U.S. Food and Drug Administration has granted CLIA (Clinical Laboratory Improvement Amendments) waiver for the cobas Strep A test for use on the cobas Liat System Further company coverage: (Reporting By Zurich Newsroom)

19 May 2015

European shares dented by U.S. data, euro bounce

* Too early to fight against bull market - Citi (Adds closing prices)

15 May 2015

European shares dented by U.S. data, euro bounce

LONDON, May 15 - A resurgent euro in the wake of weak U.S. data hit European stocks on Friday, even as bond markets stabilised after a recent rollercoaster sell-off.

15 May 2015

Roche rallies as European shares resume uptrend

LONDON, May 15 - European shares advanced on Friday, as calmer conditions in the bond market buoyed the region's stock markets, with drugs group Roche rallying after positive trial results.

15 May 2015

Rally in Roche helps to lift European shares

LONDON, May 15 - European shares advanced on Friday, as calmer conditions in the bond market buoyed the region's stock markets, while drugs group Roche rallied after positive product results.

15 May 2015

BRIEF-Strong immunotherapy results lift Roche shares

* Shares in the Swiss drugmaker rise 2.8 percent by 0720 GMT on strong results following release of scientific summaries, or abstracts, ahead of big ASCO oncology conference in Chicago later this month

15 May 2015

Earnings vs. Estimates

Search Stocks